Clinical trials recruiting in Burgos, Spain

Phase breakdown

Conditions recruiting in Burgos, Spain

Recruiting trials in Burgos, Spain

• A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
  NCT06578078 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female)
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
  NCT07647328 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
  NCT06686615 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
  NCT07284342 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
  NCT07650916 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
  NCT04889924 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
  NCT07195695 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
  NCT06767514 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
  NCT03605771 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis
  NCT06955221 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female
• Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
  NCT04898283 · Phase: Phase 3 · Ages: 12 Years to 65 Years · Sex: All (male and female)
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
  NCT06887088 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of a Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families
  NCT07529704 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female)
• Immunological Characteristics of Preclinical IBD
  NCT05698745 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• International Validation of Two Non-motor Scales in PD (NFS and SPARK)
  NCT04366804 · Phase: Not specified · Ages: 30 Years to 75 Years · Sex: All (male and female)
• Pesticides and Parkinson´s Disease
  NCT06420310 · Phase: Not specified · Ages: 45 Years to 55 Years · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
  NCT06750289 · Phase: Phase 3 · Ages: 12 Years to 75 Years · Sex: All (male and female)
• Significant Activities in the Integrated Person-centered Care Model
  NCT06623864 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: Male
• Spanish Series of Patients Treated With the Radionuclide Lutetium177
  NCT04949282 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
  NCT06252649 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Burgos, Spain?

26 recruiting trials have at least one study site in Burgos, Spain.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.